Highlights from early- and late-stage pipeline include combination data for cornerstone therapies BRUKINSA and tislelizumab early results for OX40 agonist BGB-A445 and BCL-2 inhibitor. | May 25, 2023
Highlights from early- and late-stage pipeline include combination data for cornerstone therapies BRUKINSA and tislelizumab early results for OX40 agonist BGB-A445 and BCL-2 inhibitor BGB-11417 BeiGene
E-Mail
IMAGE: The AstroPath platform allows for the assessment of the level of expression of a given marker on individual cells, while maintaining information on their spatial location. Shown here is. view more
Credit: Seyoun Park, Ph.D.
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respond to specific therapies targeting the immune system.
A new platform, called AstroPath, melds astronomic image analysis and mapping with pathology specimens to analyze microscopic images of tumors.